Breaking News Instant updates and real-time market news.

2023-01-23 09:02:26 CETY Clean Energy Technologies / + 09:02 01/23/23 01/23 09:02 01/23/23 09:02	Clean Energy Technologies implements 1-for-40 reverse stock split Clean Energy Technologies announced today that the Company has implemented a reverse split of its issued and outstanding common stock at a ratio of 1-for-40 shares. The Company initiated the reverse stock split in connection with its previously announced application to uplist the Company's common stock to the NASDAQ Capital Markets. The sole purpose of this action is to enable the Company to meet the stock price requirement for official listing on the NASDAQ Capital Market. The Company's common stock is now trading on a split-adjusted basis on the OTCQB under the trading symbol "CETYD". The company's trading symbol will revert back to "CETY" after 20 business days if the stock is still trading on the OTCQB or upon the listing of the Company's common stock on NASDAQ Capital Markets, whichever occurs first.

2023-01-23 09:02:26

CETY

Clean Energy Technologies

/ +

09:02

01/23/23

01/23

09:02

01/23/23

09:02

Clean Energy Technologies implements 1-for-40 reverse stock split

Clean Energy Technologies announced today that the Company has implemented a reverse split of its issued and outstanding common stock at a ratio of 1-for-40 shares. The Company initiated the reverse stock split in connection with its previously announced application to uplist the Company's common stock to the NASDAQ Capital Markets. The sole purpose of this action is to enable the Company to meet the stock price requirement for official listing on the NASDAQ Capital Market. The Company's common stock is now trading on a split-adjusted basis on the OTCQB under the trading symbol "CETYD". The company's trading symbol will revert back to "CETY" after 20 business days if the stock is still trading on the OTCQB or upon the listing of the Company's common stock on NASDAQ Capital Markets, whichever occurs first.

OTHER BREAKING NEWS FROM THE FLY

Downgrade	Repare Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 01/19/23 Repare Therapeutics receives $1.5M payment from Ono Pharmaceuticals RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/17/22 H.C. Wainwright Repare Therapeutics price target lowered to $25 from $38 at H.C. Wainwright 06/06/22 H.C. Wainwright Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 04/12/22 Stifel Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis' RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/09/22 Repare Therapeutics reports Q3 EPS $1.71, consensus (89c)
General news	Energy Action: » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 $ECON Economic Data / + Energy Action: Oil prices… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Periodicals On The Fly $ECON Economic Data / + $ECON Economic Data / + 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says 01/22/23 Fed sets course for milder interest-rate rise next month, WSJ says 11/04/22 Fed's Evans says smaller rate hikes make sense, Reuters reports 10/22/22 Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says $ECON Economic Data / + 02/01/23 What You Missed On Wall Street On Wednesday 01/24/23 What You Missed On Wall Street On Tuesday 01/18/23 What You Missed On Wall Street On Wednesday 12/15/22 What You Missed On Wall Street On Thursday
Upgrade	Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley » 05:54 02/03/23 02/03 05:54 02/03/23 05:54 NBIX Neurocrine $107.96 / -2.045 (-1.86%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NBIX Neurocrine $107.96 / -2.045 (-1.86%) 01/09/23 Xenon Pharmaceuticals outlines key milestone opportunities for 2023 01/09/23 Voyager, Neurocrine enter collaboration to advance multiple gene therapies 12/22/22 Neurocrine: FDA accepts sNDA for valbenazine 12/06/22 Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2 NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/13/22 RBC Capital Neurocrine CAH data appears pushed back, says RBC Capital 11/14/22 Evercore ISI Neurocrine downgraded to In Line from Outperform at Evercore ISI 11/02/22 BMO Capital Neurocrine price target raised to $101 from $78 at BMO Capital 11/02/22 Wells Fargo Neurocrine price target raised to $120 from $110 at Wells Fargo NBIX Neurocrine $107.96 / -2.045 (-1.86%) 11/01/22 Neurocrine reports Q3 non-GAAP EPS $1.08, consensus 79c 08/04/22 Neurocrine reports Q2 non-GAAP EPS 84c, consensus 15c NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/06/22 Fly Intel: After-Hours Movers 09/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/06/23 Biotech Ski Summit 02/06/23 Neurocrine - NBIX
Downgrade	Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 IMRX Immuneering $4.16 / +0.05 (+1.22%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/28/22 Immuneering doses first patient in Phase 1/2a trial of IMM-1-104 11/10/22 Immuneering presents preclinical data on its second program IMM-6-415 10/20/22 Immuneering names Leah Neufeld as Chief People Officer 09/30/22 Immuneering: FDA clears IND for Phase 1/2a clinical trial of IMM-1-104 IMRX Immuneering $4.16 / +0.05 (+1.22%) 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 09/30/22 Piper Sandler Immuneering transitions to clinical stage with IND approval, says Piper Sandler 07/25/22 Piper Sandler Immuneering CFO departure not a 'red flag,' says Piper Sandler 07/08/22 Chardan Immuneering initiated with a Buy at Chardan IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/10/22 Immuneering expects FY22 GAAP operating expenses $53M-$56M 11/10/22 Immuneering reports Q3 EPS (49c), consensus (49c)
Earnings	Sanofi sees 2023 business EPS up at low single digit rate at CER » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 SNY Sanofi $47.22 / -1.505 (-3.09%) Sanofi expects 2023… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 05:52 Today Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names
Upgrade	Esperion upgraded to Equal Weight from Underweight at Morgan Stanley » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 ESPR Esperion $5.91 / -0.49 (-7.66%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ESPR Esperion $5.91 / -0.49 (-7.66%) 01/11/23 RFK Racing enters team-wide partnership with Esperion 12/07/22 Esperion announces CLEAR cardiovascular outcomes trial of NEXLETOL 11/16/22 Esperion promotes Ben Halladay to CFO role 08/26/22 Esperion: NEXLETOL recommended as oral non-statin therapy by ACC task force ESPR Esperion $5.91 / -0.49 (-7.66%) 12/07/22 H.C. Wainwright H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint 08/03/22 Credit Suisse Esperion downgraded to Underperform from Neutral at Credit Suisse 05/04/22 JPMorgan Esperion upgraded to Neutral on achievable estimates at JPMorgan 05/04/22 JPMorgan Esperion upgraded to Neutral from Underweight at JPMorgan ESPR Esperion $5.91 / -0.49 (-7.66%) 01/08/23 Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M 11/01/22 Esperion reports Q3 EPS (81c), consensus (92c) ESPR Esperion $5.91 / -0.49 (-7.66%) 12/09/22 Biotech Alert: Searches spiking for these stocks today 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ESPR Esperion $5.91 / -0.49 (-7.66%) 01/06/23 Esperion call volume above normal and directionally bullish 12/19/22 Esperion put volume heavy and directionally bearish 12/07/22 Unusually active option classes on open December 7th 11/17/22 Largest borrow rate increases among liquid names
Earnings	Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 SNY Sanofi $47.22 / -1.505 (-3.09%) IFRS EPS for Q4 was EUR… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names
Upgrade	Erasca upgraded to Overweight from Equal Weight at Morgan Stanley » 05:51 02/03/23 02/03 05:51 02/03/23 05:51 ERAS Erasca $4.16 / +0.165 (+4.13%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Syndicate On The Fly ERAS Erasca $4.16 / +0.165 (+4.13%) 12/20/22 Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/13/22 Erasca announces FDA clearance of IND application for ERAS-3490 12/09/22 Erasca announces pricing of underwritten offering of common stock 12/09/22 Erasca, Novartis enter worldwide license agreement for naporafenib ERAS Erasca $4.16 / +0.165 (+4.13%) 11/09/22 Erasca reports Q3 EPS (29c), consensus (31c) 09 Dec ERAS Erasca $4.16 / +0.165 (+4.13%) 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning
Downgrade	Cyteir downgraded to Underweight from Equal Weight at Morgan Stanley » 05:50 02/03/23 02/03 05:50 02/03/23 05:50 CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 01/19/23 Cyteir Therapeutics announces prioritization of CYT-0851 development 08/08/22 Cyteir Therapeutics expects cash to fund operations into second half of 2024 CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral at BofA after strategic prioritization 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral from Buy at BofA 01/20/23 JPMorgan Cyteir Therapeutics downgraded to Neutral from Overweight at JPMorgan 09/09/22 Morgan Stanley Cyteir downgraded at Morgan Stanley with time needed for data CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 11/07/22 Cyteir Therapeutics reports Q3 EPS (31c), consensus (41c) 08/08/22 Cyteir Therapeutics reports Q2 EPS (34c), consensus (44c)
Downgrade	Meta Platforms downgraded to Reduce from Hold at HSBC » 05:48 02/03/23 02/03 05:48 02/03/23 05:48 META Meta Platforms $188.78 / +35.675 (+23.30%) HSBC analyst Nicolas… HSBC analyst Nicolas Cote-Colisson downgraded Meta Platforms to Reduce from Hold with an unchanged price target of $110. The company's Q4 results showed higher engagement, but revenue was still down, the analyst tells investors in a research note. The firm says headwinds for the company include the macro environment, competition and regulation versus one "longer-term tailwind that is Meta's lead in Metaverse." The recent share rally leads HSBC to downgrade the shares to Reduce. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B 02/01/23 Meta says 2023 will be 'a year of efficiency' 02/01/23 Meta Platforms announces $40B increase in share repurchase authorization 02/01/23 Meta Platforms reports FoA and RL segment restructuring charges META Meta Platforms $188.78 / +35.675 (+23.30%) 05:13 Today DZ Bank Meta Platforms upgraded to Hold from Sell at DZ Bank 02/02/23 Deutsche Bank Meta Platforms price target raised to $200 from $125 at Deutsche Bank 02/02/23 RBC Capital Meta Platforms price target raised to $225 from $160 at RBC Capital 02/02/23 Needham Meta Platforms reported fundamentals still deteriorating, says Needham META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B 02/01/23 Meta Platforms reports Q4 EPS $1.76, consensus $2.22 02/01/23 Notable companies reporting after market close 11/09/22 Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 FTC denies Meta request to bar Khan from antitrust case, Bloomberg says 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Meta wins approval over FTC to acquire Within Unlimited, Bloomberg says 02/01/23 Meta debates on whether to share Reel money with creators, Information reports META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 Earnings season driving record option volume 02/02/23 Early notable gainers among liquid option names on February 2nd 02/02/23 Notable open interest changes for February 2nd 02/01/23 Meta Platforms (Facebook) options imply 8.9% move in share price post-earnings

Periodicals	Tesla's sales of China-made EVs up 10% y/y in January, Reuters reports » 05:44 02/03/23 02/03 05:44 02/03/23 05:44 TSLA Tesla $188.32 / +7.05 (+3.89%) Tesla sold 66,051… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TSLA Tesla $188.32 / +7.05 (+3.89%) 01/31/23 Tesla sees capex of $6.0B-$8.0B in 2023 and $7B-9B in 2024 and 2025 01/31/23 Tesla asked for documents on driver assist systems by DOJ 01/25/23 Tesla extends afterhours gains, up over 5% at $152.45 01/25/23 Tesla CEO says Dojo AI to be competitive with Nvidia at end of 2023 TSLA Tesla $188.32 / +7.05 (+3.89%) 01/30/23 Bernstein Bernstein sees orders as 'most critical' to Tesla stock 01/30/23 Berenberg Tesla upgraded to Buy from Hold at Berenberg 01/26/23 Morgan Stanley Tesla FY23 earnings could bottom near $3 per share, says Morgan Stanley 01/26/23 Wedbush Tesla price target raised to $200 from $175 at Wedbush TSLA Tesla $188.32 / +7.05 (+3.89%) 01/25/23 Tesla reports Q4 EPS $1.19, consensus $1.13 01/25/23 Notable companies reporting after market close 10/19/22 Tesla reports Q3 EPS $1.05, consensus 99c 10/19/22 Notable companies reporting after market close TSLA Tesla $188.32 / +7.05 (+3.89%) 02/01/23 Tesla to ramp up Shanghai production, Reuters reports 01/31/23 Tesla considering plant near new Mexico City airport, Reuters reports 01/30/23 Twitter starts applying for U.S. state licenses in payment master plan, FT says 01/30/23 Tesla faces owner backlash after big price cuts, WSJ reports TSLA Tesla $188.32 / +7.05 (+3.89%) 02/02/23 What You Missed On Wall Street This Morning 01/31/23 What You Missed On Wall Street On Tuesday 01/30/23 What You Missed On Wall Street On Monday 01/30/23 What You Missed On Wall Street This Morning TSLA Tesla $188.32 / +7.05 (+3.89%) 02/02/23 Notable open interest changes for February 2nd 02/01/23 Notable open interest changes for February 1st 01/31/23 Notable open interest changes for January 31st 01/30/23 Notable open interest changes for January 30th
Downgrade	Stifel downgrades C.H. Robinson to Hold after 'sizable miss' » 05:43 02/03/23 02/03 05:43 02/03/23 05:43 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) Stifel analyst J. Bruce… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson sees 2023 capital expenditures $90M-$100M 01/03/23 C.H. Robinson CEO Bob Biesterfeld steps down, Scott Anderson named interim CEO 11/17/22 C.H. Robinson raises quarterly dividend to 61c per share from 55c 11/02/22 C.H. Robinson sees $175M of gross cost savings in Q4 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 05:22 Today Stifel C.H. Robinson downgraded to Hold from Buy at Stifel 02/02/23 BMO Capital C.H. Robinson price target lowered to $85 from $90 at BMO Capital 02/02/23 Susquehanna C.H. Robinson price target raised to $86 from $83 at Susquehanna 02/02/23 Wells Fargo C.H. Robinson price target raised to $95 from $86 at Wells Fargo CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson reports Q4 adjusted EPS $1.03, consensus $1.38 02/01/23 Notable companies reporting after market close 11/02/22 C.H. Robinson reports Q3 EPS $1.78, consensus $2.17 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 01/10/23 C.H. Robinson reaches standstill agreement with Ancora, WSJ reports CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 Fly Intel: After-Hours Movers 01/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/15/22 Fly Intel: After-Hours Movers CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 CH Robinson Worldwide options imply 6.1% move in share price post-earnings
Downgrade	RBC downgrades Spirit AeroSystems on supply chain issues » 05:40 02/03/23 02/03 05:40 02/03/23 05:40 SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) RBC Capital analyst Ken… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 11/07/22 Spirit AeroSystems rises 13.1% 10/19/22 Spirit AeroSystems enters MOU with Joramco for MRO services cooperation 09/21/22 Spirit AeroSystems enters MOU with MAB to develop MRO services for 737 aircraft 09/20/22 Spirit AeroSystems SEAS joint venture to open in October SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 05:08 Today RBC Capital Spirit AeroSystems downgraded to Sector Perform from Outperform at RBC Capital 01/09/23 Truist Spirit AeroSystems price target raised to $42 from $39 at Truist 11/11/22 BofA BofA double downgrades '737 story' Spirit AeroSystems to Underperform 11/11/22 BofA Spirit AeroSystems downgraded to Underperform from Buy at BofA SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 11/03/22 Spirit AeroSystems reports Q3 EPS (15c), consensus (40c) 11/02/22 Notable companies reporting before tomorrow's open 11/02/22 Notable companies reporting before tomorrow's open 08/03/22 Spirit AeroSystems reports Q2 adjusted EPS ($1.21), consensus (24c) SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 11/11/22 What You Missed On Wall Street On Friday 11/11/22 What You Missed On Wall Street This Morning 11/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/08/22 What You Missed On Wall Street On Thursday 02/15/23 44th Annual Aerospace/Defense & Industrials Conference 02/07/23 Spirit AeroSystems - SPR SPR Spirit AeroSystems $36.06 / -0.08 (-0.22%) 12/29/22 Largest borrow rate increases among liquid names
Upgrade	Publicis upgraded to Overweight from Equal Weight at Barclays » 05:24 02/03/23 02/03 05:24 02/03/23 05:24 PUBGY Publicis $19.20 / +0.822 (+4.47%) Barclays analyst Julien… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research PUBGY Publicis $19.20 / +0.822 (+4.47%) 10/18/22 Chicken Soup teams with Publicis' APX Content Ventures on new reality series PUBGY Publicis $19.20 / +0.822 (+4.47%) 01/31/23 Barclays Publicis price target raised to EUR 68 from EUR 62.50 at Barclays 01/06/23 UBS Publicis price target raised to EUR 71 from EUR 68 at UBS 12/16/22 Morgan Stanley Publicis price target raised to EUR 53 from EUR 50 at Morgan Stanley 12/12/22 JPMorgan Publicis price target raised to EUR 82 from EUR 75 at JPMorgan
Downgrade	C.H. Robinson downgraded to Hold from Buy at Stifel » 05:22 02/03/23 02/03 05:22 02/03/23 05:22 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) Stifel analyst J. Bruce… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson sees 2023 capital expenditures $90M-$100M 01/03/23 C.H. Robinson CEO Bob Biesterfeld steps down, Scott Anderson named interim CEO 11/17/22 C.H. Robinson raises quarterly dividend to 61c per share from 55c 11/02/22 C.H. Robinson sees $175M of gross cost savings in Q4 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/02/23 BMO Capital C.H. Robinson price target lowered to $85 from $90 at BMO Capital 02/02/23 Susquehanna C.H. Robinson price target raised to $86 from $83 at Susquehanna 02/02/23 Wells Fargo C.H. Robinson price target raised to $95 from $86 at Wells Fargo 02/02/23 Bernstein C.H. Robinson price target lowered to $92 from $110 at Bernstein CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 C.H. Robinson reports Q4 adjusted EPS $1.03, consensus $1.38 02/01/23 Notable companies reporting after market close 11/02/22 C.H. Robinson reports Q3 EPS $1.78, consensus $2.17 CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 01/10/23 C.H. Robinson reaches standstill agreement with Ancora, WSJ reports CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 Fly Intel: After-Hours Movers 01/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/15/22 Fly Intel: After-Hours Movers CHRW C.H. Robinson $104.37 / +2.36 (+2.31%) 02/01/23 CH Robinson Worldwide options imply 6.1% move in share price post-earnings
Downgrade	Sallie Mae downgraded to Equal Weight from Overweight at Wells Fargo » 05:20 02/03/23 02/03 05:20 02/03/23 05:20 SLM Sallie Mae $14.82 / -2.965 (-16.67%) Wells Fargo analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly SLM Sallie Mae $14.82 / -2.965 (-16.67%) 01/10/23 Sallie Mae names Kerri Palmer as COO SLM Sallie Mae $14.82 / -2.965 (-16.67%) 01/10/23 JPMorgan Sallie Mae price target raised to $18 from $17 at JPMorgan 01/06/23 Barclays Sallie Mae price target raised to $22 from $20 at Barclays 11/11/22 Compass Point Sallie Mae downgraded to Neutral at Compass Point following outperformance 11/10/22 Compass Point Sallie Mae downgraded to Neutral from Buy at Compass Point SLM Sallie Mae $14.82 / -2.965 (-16.67%) 02/01/23 Sallie Mae sees FY23 adjusted EPS $2.50-$2.70, consensus $2.58 02/01/23 Sallie Mae reports Q4 EPS (33c), consensus 47c 10/26/22 Sallie Mae sees FY22 revenue $2.50-$2.60, consensus $2.64 10/26/22 Sallie Mae reports Q3 EPS 29c, consensus 48c SLM Sallie Mae $14.82 / -2.965 (-16.67%) 12/01/22 Supreme Court keeps Biden student debt relief plan on hold, Bloomberg says 12/01/22 Supreme Court keeps Biden student debt relief plan on hold, Bloomberg says 08/24/22 Biden cancels $10,000 of student loan debt, $20,000 in Pell Grants 08/24/22 Biden to forgive $10,000 in student loans, $20,000 Pell debt, Bloomberg says SLM Sallie Mae $14.82 / -2.965 (-16.67%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 08/24/22 What You Missed On Wall Street On Wednesday 08/24/22 What You Missed On Wall Street This Morning
Downgrade	Cognizant downgraded to Neutral from Outperform at Baird » 05:19 02/03/23 02/03 05:19 02/03/23 05:19 CTSH Cognizant $70.62 / +1.78 (+2.59%) Baird analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options CTSH Cognizant $70.62 / +1.78 (+2.59%) 02/02/23 Cognizant raises dividend 7% to 29c 01/26/23 Cognizant, CoreLogic announce new 10-year services agreement worth $1B 01/23/23 Cognizant to acquire Mobica, terms not disclosed 01/12/23 Cognizant appoints Ravi Kumar S as CEO CTSH Cognizant $70.62 / +1.78 (+2.59%) 01/19/23 MoffettNathanson Cognizant downgraded to Underperform from Market Perform at MoffettNathanson 01/15/23 UBS Cognizant price target raised to $68 from $62 at UBS 01/13/23 BMO Capital Cognizant price target raised to $71 from $65 at BMO Capital 01/09/23 BofA Cognizant downgraded to Underperform from Neutral at BofA CTSH Cognizant $70.62 / +1.78 (+2.59%) 02/02/23 Cognizant sees Q1 revenue $4.71B-$4.76B, consensus $4.88B 02/02/23 Cognizant reports Q4 adjusted EPS $1.01, consensus $1.02 02/02/23 Notable companies reporting after market close 01/12/23 Cognizant now sees Q4 revenue $4.8B vs. prior $4.72B-$4.77B view CTSH Cognizant $70.62 / +1.78 (+2.59%) 02/02/23 Fly Intel: After-Hours Movers 01/21/23 Buy/Sell: Wall Street's top 10 stock calls this week 01/19/23 What You Missed On Wall Street On Thursday 01/19/23 What You Missed On Wall Street This Morning CTSH Cognizant $70.62 / +1.78 (+2.59%) 01/12/23 Early notable gainers among liquid option names on January 12th 01/11/23 Largest borrow rate increases among liquid names
Upgrade	Lundin Mining upgraded to Overweight from Equal Weight at Morgan Stanley » 05:19 02/03/23 02/03 05:19 02/03/23 05:19 LUNMF Lundin Mining $7.32 / -0.28 (-3.68%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research LUNMF Lundin Mining $7.32 / -0.28 (-3.68%) 10/13/22 Sandstorm Gold provides update on royalty portfolio LUNMF Lundin Mining $7.32 / -0.28 (-3.68%) 02/02/23 Credit Suisse Lundin Mining price target raised to C$10.25 from C$8.25 at Credit Suisse 01/23/23 JPMorgan Lundin Mining price target lowered to SEK 57 from SEK 65 at JPMorgan 01/18/23 Scotiabank Lundin Mining price target raised to C$15 from C$12 at Scotiabank 01/17/23 Scotiabank Lundin Mining price target lowered to C$9 from C$10 at Scotiabank
Downgrade	Aptiv downgraded to Peer Perform from Outperform at Wolfe Research » 05:16 02/03/23 02/03 05:16 02/03/23 05:16 APTV Aptiv $118.67 / +3.97 (+3.46%) Wolfe Research analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options APTV Aptiv $118.67 / +3.97 (+3.46%) 12/23/22 Aptiv completes acquisition of Wind River from TPG 12/15/22 Aptiv appoints Benjamin Lyon as CTO 11/14/22 Appaloosa exits positions in Kohl's, Occidental Petroleum, Micron 09/13/22 Aptiv to acquire Intercable Automotive Solutions for EUR595M APTV Aptiv $118.67 / +3.97 (+3.46%) 01/23/23 Deutsche Bank Aptiv named short-term buy idea at Deutsche Bank 01/19/23 Deutsche Bank Deutsche Bank keeps Buy on Aptiv, lowers price target to $126 01/09/23 BofA Aptiv downgraded to Neutral from Buy at BofA 12/15/22 RBC Capital Aptiv price target lowered to $115 from $120 at RBC Capital APTV Aptiv $118.67 / +3.97 (+3.46%) 02/02/23 Aptiv sees FY23 adjusted EPS $4.00-$4.50, consensus $4.73 02/02/23 Aptiv reports Q4 adjusted EPS $1.27, consensus $1.22 11/03/22 Aptiv backs FY22 adjusted EPS view $3.05-$3.55, consensus $3.16 11/03/22 Aptiv reports Q3 adjusted EPS $1.28, consensus 99c APTV Aptiv $118.67 / +3.97 (+3.46%) 01/27/23 Early notable gainers among liquid option names on January 27th 08/05/22 Largest borrow rate increases among liquid names
Upgrade	Meta Platforms upgraded to Hold from Sell at DZ Bank » 05:13 02/03/23 02/03 05:13 02/03/23 05:13 META Meta Platforms $188.78 / +35.675 (+23.30%) DZ Bank analyst Ingo… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B 02/01/23 Meta says 2023 will be 'a year of efficiency' 02/01/23 Meta Platforms announces $40B increase in share repurchase authorization 02/01/23 Meta Platforms reports FoA and RL segment restructuring charges META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 Deutsche Bank Meta Platforms price target raised to $200 from $125 at Deutsche Bank 02/02/23 RBC Capital Meta Platforms price target raised to $225 from $160 at RBC Capital 02/02/23 Needham Meta Platforms reported fundamentals still deteriorating, says Needham 02/02/23 Jefferies Meta Platforms price target raised to $225 from $175 at Jefferies META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B 02/01/23 Meta Platforms reports Q4 EPS $1.76, consensus $2.22 02/01/23 Notable companies reporting after market close 11/09/22 Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 FTC denies Meta request to bar Khan from antitrust case, Bloomberg says 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Meta wins approval over FTC to acquire Within Unlimited, Bloomberg says 02/01/23 Meta debates on whether to share Reel money with creators, Information reports META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 Earnings season driving record option volume 02/02/23 Early notable gainers among liquid option names on February 2nd 02/02/23 Notable open interest changes for February 2nd 02/01/23 Meta Platforms (Facebook) options imply 8.9% move in share price post-earnings

Downgrade	ING Groep downgraded to Hold from Buy at Societe Generale » 05:13 02/03/23 02/03 05:13 02/03/23 05:13 ING ING Groep $13.87 / -0.77 (-5.26%) Societe Generale analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings ING ING Groep $13.87 / -0.77 (-5.26%) 12/30/22 ING completes share buyback program, to pay remaining EUR 297M to holders 11/03/22 ING Groep on track to meet previously communicated financial targets 11/03/22 ING Groep director Mariana Gheorghe decides not to stand for reappointment 11/03/22 ING Groep announces share buyback programme of up to EUR 1.5B ING ING Groep $13.87 / -0.77 (-5.26%) 01/27/23 Barclays ING Groep price target raised to EUR 12.50 from EUR 11.50 at Barclays 12/06/22 JPMorgan ING Groep price target raised to EUR 13.40 from EUR 13 at JPMorgan 11/18/22 Morgan Stanley ING Groep price target raised to EUR 16 from EUR 14 at Morgan Stanley 11/18/22 Morgan Stanley ING Groep price target raised, named a 'Top Pick' at Morgan Stanley ING ING Groep $13.87 / -0.77 (-5.26%) 02/02/23 ING Groep reports Q4 net result per share EUR 0.30 vs. EUR 0.25 last year 11/03/22 ING Groep reports Q3 net result per share EUR 0.26 vs EUR 0.35 last year 08/04/22 ING Groep reports Q2 net result per share EUR 0.31 vs. EUR 0.11 last year
Downgrade	Kesko downgraded to Hold from Buy at Danske Bank » 05:12 02/03/23 02/03 05:12 02/03/23 05:12 KKOYY Kesko $11.47 / -0.64 (-5.28%) Danske Bank analyst Calle… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research KKOYY Kesko $11.47 / -0.64 (-5.28%) 01/24/23 DNB Markets Kesko initiated with a Buy at DNB Markets
Upgrade	EMS-Chemie upgraded to Buy from Hold at Kepler Cheuvreux » 05:11 02/03/23 02/03 05:11 02/03/23 05:11 EMSHF EMS-Chemie $670.30 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EMSHF EMS-Chemie $670.30 / + (+0.00%) 12/13/22 Berenberg EMS-Chemie price target raised to CHF 600 from CHF 590 at Berenberg 12/13/22 Stifel EMS-Chemie downgraded to Hold from Buy at Stifel 10/31/22 Berenberg EMS-Chemie downgraded to Hold from Buy at Berenberg 10/18/22 Baader Helvea EMS-Chemie downgraded to Reduce from Add at Baader Helvea
Downgrade	Insurance Australia downgraded to Neutral from Overweight at JPMorgan » 05:11 02/03/23 02/03 05:11 02/03/23 05:11 IAUGY Insurance Australia $17.31 / +0.13 (+0.76%) JPMorgan analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research IAUGY Insurance Australia $17.31 / +0.13 (+0.76%) 01/24/23 Goldman Sachs Insurance Australia initiated with a Neutral at Goldman Sachs 01/11/23 JPMorgan Insurance Australia upgraded to Overweight from Neutral at JPMorgan
Upgrade	Cardinal Health upgraded to Outperform from Neutral at Baird » 05:09 02/03/23 02/03 05:09 02/03/23 05:09 CAH Cardinal Health $76.33 / +0.62 (+0.82%) Baird analyst Eric… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CAH Cardinal Health $76.33 / +0.62 (+0.82%) 12/19/22 Cardinal Health announces Aaron Alt as chief financial officer 12/12/22 Yellow Corp appoints Annlea Rumfola as CIO 11/14/22 Elliott made Triple Flag Precious Metals top holding during Q3 09/15/22 PayrHealth announces collaboration with Cardinal Health CAH Cardinal Health $76.33 / +0.62 (+0.82%) 01/31/23 UBS Cardinal Health price target raised to $91 from $78 at UBS 11/22/22 Credit Suisse Cardinal Health price target raised to $79 from $64 at Credit Suisse 11/14/22 Mizuho Cardinal Health price target raised to $74 from $66 at Mizuho 11/07/22 Baird Cardinal Health price target raised to $82 from $74 at Baird CAH Cardinal Health $76.33 / +0.62 (+0.82%) 02/02/23 Cardinal Health raises FY23 EPS view to $5.20-$5.50 from $5.05-$5.40 02/02/23 Cardinal Health reports Q2 EPS $1.32, consensus $1.14 02/01/23 Notable companies reporting before tomorrow's open 02/01/23 Notable companies reporting before tomorrow's open CAH Cardinal Health $76.33 / +0.62 (+0.82%) 09/22/22 Activist Elliott would like to see Pinterest put up for sale, Barron's says 08/15/22 Elliott has large stake in Cardinal Health, seeks board seats, WSJ says CAH Cardinal Health $76.33 / +0.62 (+0.82%) 11/04/22 Fly Intel: Pre-market Movers 09/28/22 #SocialStocks: Details of Musk's deposition by Twitter still being hammered out 08/15/22 What You Missed On Wall Street On Monday 08/11/22 Fly Intel: Pre-market Movers CAH Cardinal Health $76.33 / +0.62 (+0.82%) 12/02/22 Early notable gainers among liquid option names on December 2nd 11/11/22 Cardinal Health put volume heavy and directionally bearish 10/10/22 Cardinal Health call volume above normal and directionally bullish 08/12/22 Early notable gainers among liquid option names on August 12th

Events

Earnings calls, analyst events, roadshows and more

AVTR
Today at 08:00

Avantor - AVTR Conference Calls
TWST
Today at 08:00

Twist Bioscience - TWST Conference Calls
SNY
Today at 08:00

Sanofi - SNY Conference Calls
Today at 08:30

Employment Situation: Private Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Manufacturing Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Participation Rate: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Non-Farm Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings Y/Y: January 2023 Government Event
Today at 08:30

Employment Situation--Unemployment Rate: January 2023 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	VERA X VERA Vera Therapeutics Spot Secondary Managers: JPMorgan, Cowen & Evercore ISI, LIFC Priced at: $7.00 14.286M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ALGM X ALGM Allegro MicroSystems Block Trade Managers: Credit Suisse Priced at: $38.00 4.98M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GPCR X GPCR Structure Therapeutics IPO Managers: Jefferies, SVB Securities, Guggenheim & BMO Capital Priced at: $15.00 10.74M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ROIV X ROIV Roivant Sciences Secondary Managers: Goldman Sachs, SVB Securities, Cowen & Cantor Fitzgerald Priced at: $7.50 26.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AVTX X AVTX Avalo Therapeutics Spot Secondary Managers: SVB Securities & RBC Capital Priced at: $3.98 3.77M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDBL X EDBL Edible Garden Spot Secondary Managers: Maxim & Joseph Gunnar Priced at: $6.30 1.62M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	WULF X WULF TeraWulf Spot Secondary Managers: JonesResearch $1.03
Thurs	ASST X ASST Asset Entities IPO Managers: Boustead $5.00 1.5M Shares SODR X SODR Sondors IPO Managers: DA Davidson & Lake Street $8.00 - 10.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDXH X MDXH MDxHealth Secondary Managers: Cowen & William Blair, BTIG, KBCS $6.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CLLS X CLLS Cellectis Spot Secondary Managers: Jefferies & Barclays $3.26 22M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TWO X TWO Two Harbors Spot Secondary Managers: Goldman Sachs, JPMorgan & Citi, JMP Securities $17.80-18.00 10M Shares
Fri	No deals

View All Syndicate Announcements »

Clean Energy Technologies implements 1-for-40 reverse stock split

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access